SeD

Global BioLife Inc.’s Naturally Modified Sugar Laetose(TM) Unveiled at Harvard Global Health Summit

Singapore, July 24, 2019: SGX-listed Singapore eDevelopment Ltd ("SeD", SGX:40V) is pleased to announce the results of clinical trials conducted…

5 years ago

Singapore eDevelopment (SGX:40V) Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson’s Research at Neuroscience 2018

Singapore, November 24, 2018: Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”), through its subsidiary, Global BioLife Inc. (“Global…

6 years ago